- Associated Press•4 hours ago
On a per-share basis, the South San Francisco, California-based company said it had profit of 12 cents. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by ...
- Investor's Business Daily•4 hours ago
Exelixis is teaming up with Bristol-Myers Squibb and Roche to test its Cabometyx and their immuno-oncology drugs in liver and bladder cancer.
- Business Wire•5 hours agoExelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Exelixis, Inc. today reported financial results for the fourth quarter and full year of 2016 and provided an update on progress toward delivering upon its key corporate objectives, as well as commercial and clinical development milestones.
EXEL : Summary for Exelixis, Inc. - Yahoo Finance
Exelixis, Inc. (EXEL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||22.60 x 100|
|Ask||22.85 x 900|
|Day's Range||21.82 - 23.40|
|52 Week Range||3.55 - 23.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-35.09|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|